Vaxart Secures $25M Share Purchase Deal with Lincoln Park Capital
Event summary
- Vaxart entered a share purchase agreement with Lincoln Park Capital Fund for up to $25M in common stock over 24 months.
- Vaxart retains full control over the timing and amount of stock sales.
- Lincoln Park is obligated to purchase shares at prevailing market prices with no upper limit.
- The agreement includes no warrants, rights of first refusal, or participation rights in future financings.
- Vaxart issued shares to Lincoln Park as consideration for entering the agreement.
The big picture
This agreement provides Vaxart with a flexible capital structure to support its clinical-stage oral vaccine development. The deal underscores the company's strategy to secure non-dilutive financing while maintaining control over its financial operations. In the broader biotech landscape, such agreements are becoming more common as companies seek to balance funding needs with strategic independence.
What we're watching
- Capital Flexibility
- How Vaxart's discretion over the timing and amount of stock sales will impact its financial strategy and operational flexibility.
- Market Conditions
- Whether prevailing market prices will favorably influence the terms of future stock sales under the agreement.
- Clinical Milestones
- The pace at which Vaxart advances its oral vaccine programs and how this financing supports those milestones.
Our editorial coverage:
Related topics